BioCentury | Jul 3, 2013
Top Story

Sequenta raises $20 million in series C

...Index Ventures also participated. Foresite Capital's Jim Tananbaum joined Sequenta's board. In February, Sequenta launched ClonoSIGHT...
...patients with acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). ClonoSIGHT...
BioCentury | Feb 25, 2013
Company News

Sequenta sales and marketing update

...Sequenta launched ClonoSIGHT in the U.S. to detect residual disease in patients with acute lymphoblastic leukemia...
...MCL) and chronic lymphocytic leukemia (CLL). Sequenta offers the test out of its CLIA-certified laboratory. ClonoSIGHT...
Items per page:
1 - 2 of 2